Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [21] Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma
    Palmer, Daniel H.
    Johnson, Phillip J.
    CANCER AND METASTASIS REVIEWS, 2015, 34 (03) : 497 - 509
  • [22] Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma
    Daniel H. Palmer
    Phillip J. Johnson
    Cancer and Metastasis Reviews, 2015, 34 : 497 - 509
  • [23] Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer
    Rothrock, Nan E.
    Jensen, Sally E.
    Beaumont, Jennifer L.
    Abernethy, Amy P.
    Jacobsen, Paul B.
    Syrjala, Karen
    Cella, David
    VALUE IN HEALTH, 2013, 16 (05) : 789 - 796
  • [24] New targeted therapies in kidney cancer
    Mayrhofer, Karl
    Niedersuess-Beke, Dora
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (02) : 133 - 136
  • [25] Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer
    Owonikoko, Taofeek K.
    Chowdry, Rajasree P.
    Chen, Zhengjia
    Kim, Sungjin
    Saba, Nabil F.
    Shin, Dong M.
    Khuri, Fadlo R.
    ONCOLOGIST, 2013, 18 (12) : 1262 - 1269
  • [26] New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
    Kroschinsky, Frank
    Stoelzel, Friedrich
    von Bonin, Simone
    Beutel, Gernot
    Kochanek, Matthias
    Kiehl, Michael
    Schellongowski, Peter
    CRITICAL CARE, 2017, 21
  • [27] Managing side-effects of targeted therapies in renal cancer: surgical complications
    Chevreau, Christine
    Mejean, Arnaud
    Pocard, Marc
    BULLETIN DU CANCER, 2011, 98 : S61 - S67
  • [28] Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors
    Cuyle, Pieter-Jan
    Prenen, Hans
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (02): : 140 - 150
  • [29] Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
    Yu, Steven S.
    Quinn, David I.
    Dorff, Tanya B.
    ONCOTARGETS AND THERAPY, 2016, 9 : 5825 - 5837
  • [30] Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
    Coppin, Chris
    Kollmannsberger, Christian
    Le, Lyly
    Porzsolt, Franz
    Wilt, Timothy J.
    BJU INTERNATIONAL, 2011, 108 (10) : 1556 - 1563
12345